Profile data is unavailable for this security.
About the company
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
- Revenue in HKD (TTM)1.77bn
- Net income in HKD-2.11bn
- Incorporated2012
- Employees2.53k
- LocationShanghai Junshi Biosciences Co Ltd16F, Building 7, No. 6, Lane 100Pingjiaqiao Road, Pudong New AreaSHANGHAI 201203ChinaCHN
- Phone+86 2 161058800
- Fax+86 2 161757377
- Websitehttps://www.junshipharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3SBio Inc | 9.20bn | 1.81bn | 13.97bn | 5.61k | 7.84 | 0.8889 | 6.21 | 1.52 | 0.7437 | 0.7437 | 3.78 | 6.56 | 0.3575 | 1.52 | 6.87 | 1,700,070.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 16.19bn | 10.78k | 6.62 | 1.03 | 5.63 | 1.53 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Simcere Pharmaceutical Group Ltd | 6.93bn | -1.21bn | 17.74bn | 6.41k | -- | 2.37 | -- | 2.56 | -0.4604 | -0.4604 | 2.69 | 2.97 | 0.5198 | 2.19 | 2.64 | 985,844.90 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| China Medical System Holdings Ltd | 7.66bn | 1.52bn | 19.00bn | 5.78k | 12.53 | 1.08 | 10.79 | 2.48 | 0.6216 | 0.6216 | 3.13 | 7.19 | 0.384 | 2.89 | 5.65 | 1,343,944.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| The United Laboratories Intl. Hldgs Ltd. | 15.30bn | 3.18bn | 19.19bn | 15.00k | 6.04 | 1.30 | 5.05 | 1.25 | 1.75 | 1.75 | 8.42 | 8.13 | 0.6578 | 3.30 | 5.67 | 1,020,171.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Zai Lab Ltd | 2.51bn | -2.32bn | 23.81bn | 2.18k | -- | 4.29 | -- | 9.49 | -2.39 | -2.39 | 2.58 | 5.58 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| HUTCHMED (China) Ltd | 4.75bn | -326.19m | 24.75bn | 1.97k | -- | 4.30 | -- | 5.21 | -0.3881 | -0.3881 | 5.50 | 6.60 | 0.4775 | 7.10 | 4.15 | 2,387,889.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| WuXi XDC Cayman Inc | 3.05bn | 649.44m | 27.71bn | 1.50k | 43.29 | 4.23 | 37.46 | 9.07 | 0.5336 | 0.5336 | 2.70 | 5.46 | 0.5586 | 21.31 | 2.85 | 2,592,253.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | -- | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| Shanghai Junshi Biosciences Co Ltd | 1.77bn | -2.11bn | 27.91bn | 2.53k | -- | 1.81 | -- | 15.78 | -2.14 | -2.14 | 1.79 | 7.20 | 0.142 | 0.9772 | 3.47 | 688,617.60 | -18.39 | -18.81 | -23.06 | -23.08 | 63.58 | 68.83 | -129.53 | -88.27 | 1.83 | -10.84 | 0.2795 | -- | 3.38 | 337.82 | 4.38 | -- | 8.69 | -- |
| China Resources Pharmaceutical Group Ltd | 273.68bn | 4.12bn | 34.55bn | 72.76k | 8.38 | 0.654 | 2.74 | 0.1263 | 0.6564 | 0.6564 | 43.56 | 8.41 | 0.966 | 6.09 | 3.28 | 3,749,788.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
Data as of Nov 01 2024. Currency figures normalised to Shanghai Junshi Biosciences Co Ltd's reporting currency: Hong Kong Dollar HKD
18.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GIC Pte Ltd. (Investment Management)as of 20 Feb 2024 | 15.34m | 7.00% |
| HHLR Advisors Ltd.as of 31 Dec 2023 | 11.40m | 5.20% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 6.97m | 3.18% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.10m | 0.96% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 2.08m | 0.95% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 797.00k | 0.36% |
| Handelsbanken Fonder ABas of 30 Sep 2024 | 742.80k | 0.34% |
| Value Partners Ltd.as of 30 Jun 2023 | 508.00k | 0.23% |
| HSBC Global Asset Management (UK) Ltd.as of 30 Aug 2024 | 430.32k | 0.20% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 302.60k | 0.14% |
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.
